Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25997167 | 0.93 | LTB4R (0.36) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL26062056 | 0.92 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL25997177 | 0.92 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL25997196 | 0.92 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL26062041 | 0.91 | LTB4R (0.41) | LTB4RPPARA | |
| SCHEMBL25997199 | 0.91 | LTB4R (0.34) | LTB4RPPARACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL25997242 | 0.87 | CYP4F2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL25997157 | 0.84 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11PPARA | |
| SCHEMBL25997091 | 0.84 | LTB4R (0.40) | LTB4RCYP4F2CYP4A11PPARA | |
| SCHEMBL26062068 | 0.82 | CYP4F2 (0.39) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | LTB4R 854/4885HSP90AA1 2755/4885HSP90AB1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.